Archives of Dermatological Research

, Volume 282, Issue 3, pp 168–171 | Cite as

A possible mechanism of action for azelaic acid in the human epidermis

  • K. U. Schallreuter
  • J. W. Wood
Original Contributions


Azelaic acid, and other saturated dicarboxylic acids (C9-C12), are shown to be competitive inhibitors of tyrosinase (KI azelaic acid = 2.73×10−3M) and of membrane-associated thioredoxin reductase (KI azelaic acid = 1.25×10−5M). The monomethyl ester of azelaic acid does not inhibit thioredoxin reductase, but it does inhibit tyrosinase, although double the concentration is necessary compared with azelaic acid (KI azelaic acid monomethyl ester = 5.24×10−3M). Neither azelaic acid nor its monomethyl ester inhibit tyrosinase when catechol is used as a substrate instead of l-tyrosine. Therefore, the weak inhibitory action of azelaic acid on tyrosinase appears to be due to the competition of a single carboxylate group on this inhibitor for the α-carboxylate binding site of the l-tyrosine substrate on the enzyme active site. Based on the inhibitor constant on tyrosinase, at least cytotoxic levels of azelaic acid would be required for the direct inhibition of melanin biosynthesis in melanosomes if this mechanism is responsible for depigmentation in the hyperpigmentation disorders lentigo maligna and melasma. Alternatively only 10−5M azelaic acid is required to inhibit thioredoxin reductase. This enzyme is shown to regulate tyrosinase through a feedback mechanism involving electron transfer to intra-cellular thioredoxin, followed by a specific interaction between reduced thioredoxin and tyrosinase. Furthermore, the thioredoxin reductase/thioredoxin system is shown to be a principal electron donor for the ribonucleotide reductases which regulates DNA synthesis. Inhibition of thioredoxin reductase by azelaic acid provides a rationale for both its depigmenting property and the reversible inhibition of DNA synthesis observed in cultured epidermal cells and also in some of the bacteria associated with acne vulgaris.

Key words

Azelaic acid Inhibitor Tyrosinase Thioredoxin reductase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Breathnach AS, Ward BJ, Robins EJ, Bashin Y, Ethridge L, Passi S, Nazzaro-Porro M (1985) Analytic ultrastructural auto-radiographic localization by 3H dicarboxylic acids in cultured normal human melanocytes and keratinocytes. In: Bagnara J, Klaus SN, Paul E, Schartl M (eds) Biological, molecular, and clinical aspects of pigmentation. XIIth International Pigment Cell Conference. University of Tokyo Press, pp 627–641Google Scholar
  2. 2.
    Doherty VR, Ashworth J, Cox N (1987) Azelaic acid in lentigo maligna. Br J Dermatol 116:606Google Scholar
  3. 3.
    Duckworth HW, Coleman JE (1970) Physicochemical and kinetic properties of mushroom tyrosinase. Biol Chem 245:1613–1619Google Scholar
  4. 4.
    Fuchs J (1977) Isolation of an Escherichia coli mutant deficient in thioredoxin reductase. J Bacteriol 129:967–974Google Scholar
  5. 5.
    Holmgren A (1985) Thioredoxin. Annu Rev Biochem 54:237–271Google Scholar
  6. 6.
    Holmgren A, Branden C-I, Jornvall H, Sjoberg B-M (1986) Thioredoxin and glutaredoxin systems: structure and function. Raven Press, New YorkGoogle Scholar
  7. 7.
    Kwon BS, Hag AK, Pomerantz SH, Halaban R (1987) Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA 84:7474–7479Google Scholar
  8. 8.
    Leeming JP, Holland KT, Bojar RA (1986) The in vitro antimicrobial effect of azelaic acid. Br J Dermatol 115:551–558Google Scholar
  9. 9.
    Leibl H, Stingl G, Pehamburger H, Korchan H, Konrad K, Wolf K (1985) Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatol 85:417–422Google Scholar
  10. 10.
    Lerch K (1988) Protein and active site structure of tyrosinase. In: Bagnara JT (ed) Advances in pigment cell research. Prog Clin Biol Res 256:88–97Google Scholar
  11. 11.
    Mason HS (1957) Mechanism of oxygen metabolism. Adv Enzymol 19:79–86Google Scholar
  12. 12.
    McLean DI, Peter KK (1986) Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid. Br J Dermatol 114:685–689Google Scholar
  13. 13.
    Nazzaro-Porro M, Passi S (1978) Identification of tyrosinase inhibitors in cultures of pityrosporum. J Invest Dermatol 71:205–208Google Scholar
  14. 14.
    Nazzaro-Porro M, Passi S (1979) Azelaic acid as a competitive inhibitor of tyrosinase. Pigment Cell 4:234–243Google Scholar
  15. 15.
    Nazzaro-Porro M, Passi S, Balus L, Breathnach AS (1979) Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol 72:296–305Google Scholar
  16. 16.
    Norris J, Cunliffe WJ, Burke B (1987) Azelaic acid really does work in acne — a double-blind national and international study. Br J Dermatol 117:34–35Google Scholar
  17. 17.
    Pathak MA, Wick M, Farinelli W, Fitzpatrick TB (1979) Evaluation of azelaic acid on normal skin pigmentation and on B16 mouse melanoma. J Invest Dermatol 72:266Google Scholar
  18. 18.
    Robins EJ, Breathnach AS, Bashin VP, Ethridge L, Nazzaro-Porro M, Passi S, Picardo M (1986) Azelaic acid. J Invest Dermatol 87:293–294Google Scholar
  19. 19.
    Schallreuter KU, Pittelkow MR (1988) Defective calcium uptake system in vitiligo. Arch Dermatol Res 280:137–139Google Scholar
  20. 20.
    Schallreuter KU, Witkop CJ Jr (1988) Thioredoxin reductase activity in Hermansky-Pudlak syndrome. A method for identification of putative heterozygotes. J Invest Dermatol 90:372–377Google Scholar
  21. 21.
    Schallreuter KU, Wood JM (1986) The role of thioredoxin reductase in the reduction of free radicals at the surface of the epidermis. Biochem Biophys Res Commun 136:630–637Google Scholar
  22. 22.
    Schallreuter KU, Wood JM (1987) Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett 36:297–305Google Scholar
  23. 23.
    Schallreuter KU, Wood JM (1988) The activity and purification of membrane-associated thioredoxin reductase from human metastatic melanotic melanoma. Biochim Biophys Acta 967:103–109Google Scholar
  24. 24.
    Schallreuter KU, Wood JM (1989) Free radical reduction in the human epidermis. Free Radic Biol Med 6:519–531Google Scholar
  25. 25.
    Schallreuter KU, Wood JM (1989) Thioredoxin reductase and its clinical significance in control of the pigmentary system in clinical aspects of pigmentary disorders. Clin Dermatol 7:92–105Google Scholar
  26. 26.
    Schallreuter KU, Wood JM (1989) Calcium regulates thioredoxin reductase in human metastatic melanoma. Biochim Biophys Acta 997:242–247Google Scholar
  27. 27.
    Schallreuter KU, Pittelkow MR, Gleason FK, Wood JM (1986) The role of calcium in the regulation of free radical reduction by thioredoxin reductase at the surface of the skin. Inorganic Biochem 28:227–238Google Scholar
  28. 28.
    Schallreuter KU, Schulz KH, Wood JM (1986) The induction of contact dermatitis in guinea pigs by quaternary ammonium compounds: the mechanism of antigen formation. Environ Health Perspect 70:229–237Google Scholar
  29. 29.
    Schallreuter KU, Pittelkow MR, Wood JM (1986) Free radical-reduction by thioredoxin reductase at the surface of normal and vitiliginous keratinocytes. J Invest Dermatol 87:728–732Google Scholar
  30. 30.
    Schallreuter KU, Hordinsky MR, Wood JM (1987) Thioredoxin reductase: free radical reduction by thioredoxin reductase on the skin of different hypopigmentation disorders. Arch Dermatol 123:615–619Google Scholar
  31. 31.
    Schallreuter KU, Wood JM, Breitbart EW, Kimmig W, Hicks R, Radloff H, JÄnner M (1987) Thioredoxin reductase in primary melanoma and surrounding skin. European Society for Pigment Cell Research, Sorrento, Italy, Proceedings, pp 41, 95Google Scholar
  32. 32.
    Wood JM, Schallreuter KU (1988) Reduced thioredoxin inhibits melanin biosynthesis: evidence for the formation of a stable bis-cysteinate complex with tyrosinase. Inorganica Chem Acta 151:7Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • K. U. Schallreuter
    • 1
  • J. W. Wood
    • 2
  1. 1.Department of DermatologyUniversity of HamburgHamburgFRG
  2. 2.Department of BiochemistryGray Freshwater Biological Institute, University of MinnesotaNavarreUSA

Personalised recommendations